Diacerein- A gold standard analgesic in management of osteoarthritis

Yoganarasimha N1,*
1 Dept. of Anaesthesiology and Pain Medicine, BGS Global Institute of Medical Sciences, Bangalore, Karnataka, India

ABSTRACT
Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, reconstructive and anti-destructive properties on cartilage and synovial membrane. Recently, based upon its mechanism of action it has been shown that it has got pro-anabolic effect on subchondral bone remodelling. Based on a literature review of clinical trials and meta-analyses, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) declares that after the first month of osteoarthritic treatment the diacerein efficacy is superior to that of paracetamol and similar to that of non-steroidal anti-inflammatory drugs (NSAIDs). Additionally, once treatment was stopped diacerein has shown a prolonged effect on symptoms for several months, in view of its cumulative effects. Furthermore, similarly to other Symptomatic slow-acting drugs for OA (SYSADOAs), the ESCEO positions diacerein as a first-line pharmacological background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated.

© 2020 Published by Innovative Publication. This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by/4.0/)

1. Introduction
Osteoarthritis (OA) is the most common and debilitating form of arthritis, and one of the leading causes of geriatric disability worldwide.1 Osteoarthritis is a chronic inflammation of joint, which has predominantly two components, one is limitation of joint function if untreated it might lead to deformity of joint/limb, the other is pain, which varies from tolerable to intolerable intensities. Together with disability/deformities, pain contributes to a significant reduction in quality of life.

Osteoarthritis is an inflammation of joints that results from degeneration of cartilage caused by aging, heredity, injuries or inflammation secondary to inflammation. It is the most common chronic musculoskeletal disorder. Epidemiological studies shows this disorder claims 15% of world population.2,3 In view of this ailment substantial burden on the family and economic issues are inevitable.

2. Background
Based on research osteoarthritis not only disrupt the articular cartilage, but it destroys the entire joint physiology.4 Normal adult cartilage is made up of extracellular matrix that contains majorly water, collagen, proteoglycans and chondrocytes5 the turnover phase of collagen is relatively slow than proteoglycan due to its inbuilt physiology.6 Osteoarthritis results from imbalance in the above physiology i.e. failure of chondrocytes to maintain homeostasis between synthesis and degeneration of extracellular matrix.6

Breakdown molecules of collagen and proteoglycans are digested by synovial macrophages. These macrophages engulf the molecules releasing certain cytokines namely TNF (Tumor Necrosis Factor)-α, IL (Interleukin)-β. Thus released cytokines binds the chondrocytes leading to further release of secondary inflammatory mediators like metalloproteinase, which degrades the structural proteins of the joint and inhibition of type II collagen production. This disruption of homeostasis...
results in hypoosmolarity and decrease in matrix containing rich type II collagen.  

Subchondral bone is separated from the articular cartilage by the zone of calcified cartilage. Osteoarthritis pathophysiology alters subchondral bone model also, leading to complete disruption of synovial joint architecture.

Osteoarthritis patients manifest as synovial joint pain, with swollen joint, joint stiffness, joint crackling and loss of joint motion range.

Diacerein is a slow acting drug belonging to the class anthraquinone, which works by inhibiting the action of Interleukin-1β. Interleukin-1β, is a prime cytokine which is responsible for producing symptoms and destruction of joint architecture by inducing inflammation of tissues.  

The main action of diacerein is to block the action of interleukin-1β (IL-1β) system and its concomitant down streaming signals. Diacerein decreases the production of interleukin-1 converting enzymes and thereby reduces the activation of interleukin-1β, and also it decreases the interleukin-1 receptors on the cell surface of chondrocytes and thereby reducing the sensitivity of interleukin-1 actions. By this mechanism diacerein indirectly increases the IL-1 receptor antagonist production. Diacerein inhibits the IL-1β-induced activation of transcription factor NF-κB, which stimulates pro-inflammatory cytokine expression. On molecular studies of osteoarthritic synovial fluid, down regulation of interleukin-1 level has been documented.

Besides its anti-inflammatory properties, diacerein has anti-destructive and reconstructive effects on cartilage and synovial membrane, as well as protective effects against subchondr al bone remodeling.

2.1. Trial review

Despite Diacerein being nearly three decades in the market, few randomized controlled trial (RCT) in osteoarthritis have been done. Several studies have concluded that Diacerein is a slow acting symptom modifying agent.

2.2. Study design

This review was conducted by using the search term: Diacerein, osteoarthritis, and/or clinical trial and/or metaanalysis in web. From this, trial done under long exposure (N>100), double blinded comparative studies involving the study drug with others like placebo, hyaluronic acid and NSAIDs were taken. Most reviewed RCT had relief from pain as their primary outcome, secondary efficacy variables being joint function improvement and relief from stiffness. Most of these RCT were done over a span of 3 months to 12 months. No steroid or paracetamol comparative studies were taken up.

2.3. Symptomatic efficacy

Trials are summarized in below table. Though the results were bit inconsistent there were substantial benefits to osteoarthritis patient.

The superiority of Diacerein versus placebo was reached at 2 months of therapy, similarly at the end of 3 months the efficacy were well established in hyaluronic acid comparative study.

Safety: Statistically significant adverse effects were observed in these comparative studies. Among which diarrhoea and skin rashes were more particular. Diarrhoea (46%) was experienced among the patients with Diacerein group. However, these adverse effects were self-limiting and treated symptomatically. Nearly 50% of the patient
Table 1:

| Trial             | Patients (N) | Age: Sex(F/M) | Duration (Months) | Comparison                  | P Value |
|-------------------|--------------|---------------|-------------------|-----------------------------|---------|
| Pelletier et al   | 484          | 64:80/20      | 4                 | Placebo                     | <0.05   |
| Pham et al        | 301          | 65:70/30      | 12                | Hyaluronic Acid             | 0.01    |
| Lautheranoo et al | 161          | 54:90/10      | 4                 | NSAIDS                      | 0.85    |

subjected to Diacerein drug suffered from diarrhoea and became asymptomatic when the drug was discontinued.¹⁹,²⁰

Urine discolouration was another non-fatal manifestation among the Diacerein exposed patients. This discolouration was due to the metabolite of Diacerein. The renal functions were unaffected, concluding it be an renal safe drug.¹⁸,²⁰

In long term study, skin rashes were evident in the Diacerein group, for which dermatological opinion was obtained.²⁰

2.4. Clinical data on the safety of diacerein

2.4.1. Gastrointestinal (GI)

Diacerein belong to anthraquinone family, anthraquinone chemical structure possesses laxative property. Hence, the most frequently reported events with diacerein were loose stools and diarrhea.

The following are the results obtained on relative risk ratio for developing diarrhoea when the patients are subjected to study with diacerein and placebo.

On retrospective analysis, Diarrhoea occurred in the first fortnight of treatment and was mild to moderate in its severity.²⁴ In almost all cases, the diarrhoea induced by diacerein was reversible after stopping the treatment. Furthermore, diarrhoeal symptoms decreased in most cases after continuous treatment.²⁵

The post-marketing surveillance of diacerein showed that 25 serious cases of diarrhoea were reported. Three of them concerned elderly patients, who experienced dehydration and electrolyte disorders; one case was fatal and occurred in a 79-year-old female with a medical history of arterial hypertension and cardiac arrhythmia.²⁶

2.4.2. Cutaneous

On reviewing 15 published articles, the cutaneous manifestations were evident ranging from simple rashes to high grade skin inflammations, reflecting its incidence from 1.8% to 9.4%.²⁰,²⁷ The present review identified rash, pruritus and eczema as the most common cutaneous reactions reported in clinical trials. They are appropriately reflected in the product information with a frequency of >1/100 and <1/10).

Based upon post-marketing statistics, data revealed a few severe cases of cutaneous events: four erythema multiform, two Stevens-Johnson syndrome (SJS) and three toxic epidermal necrolysis (TEN).²⁶

2.4.3. Hepatic

Among the 15 published clinical trials evaluating diacerein, only Zheng et al.²⁸ reported the occurrence of a hepatic adverse event: one treatment discontinuation due to increase in hepatic enzymes. The Pharmacovigilance Risk Assessment Committee (PRAC) performed a more complete analysis of available data and retrieved seven clinical trials showing abnormalities of liver tests. These were mostly characterized by mild/moderate liver enzyme increase (ALT, AST <5 ULN) without increases in bilirubin.²⁶

A total of 89 cases within the post-marketing surveillance were considered as hepatic reactions. The most frequent reactions were liver function test abnormalities (41 cases).²⁶

One case of hepatic failure had a fatal outcome and a close temporal association with diacerein.²⁹

The extensive preclinical animal toxicology data with diacerein indicated that the liver was not a target organ for toxicity. The mechanism of action of this hepatic toxicity is not fully understood, but an idiosyncratic mechanism is suggested.

2.4.4. Cardiovascular

Diacerein is a relatively cardiovascular safe drug. Based on ICHS (International Community Health Services) 7A guidelines, a study was designed on dog subjects, where 5 and 30 mg/kg/day for 7 consecutive days and at 60 and 200 mg/kg/day for 4 and 3 consecutive days were administered and studied. Results revealed diacerein was relatively cardiovascular safe drug with absolutely no adverse effects on cardiovascular system. Furthermore, the dosage administered was nearly 3.6 to 143 times the recommended dose on humans (1.4 mg/kg/day based on a 70 kg person).³⁰

More significantly, no signal from post-marketing surveillance for acute coronary syndromes or myocardial infarctions was reported in more than 20 years of experience with diacerein.

3. Conclusion

Diacerein has a modest but significant effect on pain management in osteoarthritis. Its comparative efficacy seems to be statistically significant enough for its inclusion in the management of osteoarthritis. The main toxicity is mild to moderate diarrhoea which has linear relationship with the dosage and duration of the therapy. The concerned
authorities advised that patient should start half the normal dose initially and titrate to the therapeutic level and discontinue once the significant adverse effect sets in. i.e. to start 50mg/day instead 100mg/day initially.

The other recommendation is to have screening test for liver dysfunction. It can be concluded that Diacerein does have a role in patient with gastrointestinal disorder, heart disease and renal disorder, where NSAIDs are avoided.

Patients with cardiac, renal and GI disorders form a major bulk of the population suffering from osteoarthritis; Diacerein by virtue of possessing a safe profile with respect to these co-morbidities, is a valuable addition to the pain physician’s armamentarium.

4. Source of funding
None.

5. Conflict of interest
None.

References

1. Hunter DJ, Schoenfeld D, Callander E. The individual and socioeconomic impact of osteoarthritis. *Nat Rev Rheumatol.* 2014;10:437–441.

2. Egloff C, Hühle T, Valderrabano V. Biomechanics and pathomechanisms of osteoarthritis. *Swiss Med WM* 2012;142:13583.

3. Solignac M, Biological markers of osteoarthritis: data from the ECHODIAH cohort. *Presse Med.* 2004;33:4–6.

4. Dieppe P. Developments in osteoarthritis. *Rheumatol (Oxford).* 2011;50:245–247.

5. Goldring MB, Marcus KB. Cartilage homeostasis in health and rheumatic diseases. *Arthritis Res Ther.* 2009;11:224.

6. Heijink A, Gonoll AH, Madry H, Drobnic M, Filardo G, et al. Biomechanical considerations in the pathogenesis of osteoarthritis of the knee. *Knee Surg Sports Traumatol Arthrosoc.* 2012;20(3):423–435.

7. Buckwalter JA, Mankin HJ, Grodzinsky AJ. Articular cartilage and osteoarthritis. *Instr Course Lect.* 2005;54:465–480.

8. Pavelka K, Bruyère O, Cooper C, Kanis JA, Leeb FB. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. *Drugs Aging.* 2016;33:75–85.

9. Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. *Ther Adv Musculoskelet Dis.* 2010;2:95–104.

10. Moldovan F, Pelletier JP, Jolicource FC, Cloutier JM, Martel-Pelletier J. Diacerein and rhein reduce the ICL-induced IL-1 beta and IL-18 activation in human osteoarthritic cartilage. *Osteoarthr Cartil.* 2000;8:186–196.

11. Yaron M, Shirazi I, Yaron I. Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. *Osteoarthr Cartil.* 1999;7:272–280.

12. Martin G, Bogdanowicz P, Domagala F, Ficheux H, Pujol JP. Rhein inhibits interleukin-Ibeta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1 in chondrocytes cultured in hypoxia: a potential mechanism for its disease-modifying effect in osteoarthritis. *Inflammation.* 2003;27:233–246.

13. Feliszar N, Boumediene K, Guwy C, Herrouin JB, Bogdanowicz G, Palavra P. Stimulating effect of diacerein on TGF beta 1 and beta 2 expression in articular chondrocytes cultured with and without interleukin-1. *Osteoarthr Cartil.* 1999;7:255–264.

14. Mendes AF, Caramona MM, Carvalho APD, Lopes MC. Diacerein and rhein prevent interleukin-1 beta-induced nuclear factor-kappa B activation by inhibiting the degradation of inhibitor kappa B-alpha. *Pharmacol Toxicol.* 2002;91:22–28.

15. Sanchez C, Mathy-Hart M, Deberg MA, Ficheux H, Reginster JY, Henrotin YE. Effects of rhein on human articular chondrocytes in alginate beads. *Biochem Pharmacol.* 2003;65:377–388.

16. Louthrenoo W, Nilganuwong S, Aksaranagraha S, Asavatanabodee P, Saengnipanthkul S. Thai Study Group. The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled trial. *Osteoarthritis Cartilage.* 2007;15:605–614.

17. Pavelka K, Toc T, Karpas K, Viték P, Sedlácková M, et al. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. *Arthritis Rheum.* 2007;56:4055–4064.

18. Macerdo CR, Maxwell LJ. Diacerein for osteoarthritis. *Cochrane database.* *Syst Rev.* 2014;(2):5117–5117.

19. Pelletier JP, Yaron M, Harauzi B, Cohen P, Nahir MA, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. *Arthritis Rheum.* 2000;43:2339–2348.

20. Pham T, Henanff AL, Ravaud P, Dieppe P, Paolozzi L, Dougados M. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. *Ann Rheum Dis.* 2004;63:1611–1617.

21. Bartels EM, Bluldal H, Schondorf PK, Altman RD, Zhang W, Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. *Osteoarthr Cartil.* 2010;18:289–296.

22. Fidelix TS, Macedo CR, Maxwell LJ, Trevisani VF. Diacerein for osteoarthritis. *Cochrane Database Syst Rev.* 2014;2:5117–5117.

23. Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. *Arch Intern Med.* 2006;166:1899–906.

24. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. *Arthritis Rheum.* 2001;44:2539–2547.

25. Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. *Arthritis Rheum.* 2001;44:1736–1743.

26. European EMA. European Medicines Agency, Assessment report for diacerein containing medicinal products; 2014,. Available from: [http://www.ema.europa.eu/docs/en](http://www.ema.europa.eu/docs/en).

27. Fagnani F, Bouvenot G, Valat JP, Bardin T, Berdah L, Lafuma A. Medico-economic analysis of diacerein with or without standard therapy in the treatment of osteoarthritis. *Pharmacoecon.* 1998;13:135–146.
28. Zheng WJ, Tang FL, Li J, Zhang FC, Li ZG, Su Y. Efficacy and safety of diacerein in osteoarthritis of the knee: a randomized, multicenter, double-dummy, diclofenac-controlled trial in China. *APLAR J Rheumatol.* 2006;9:64–69.

29. Renan X, Lepage M, Connan D, Carlhant D, Riche C, Verger P. Cas clinique d’une hépatite fatale à la diacéréine. *Thérapie.* 2001;56:190–191.

30. Mattei E, Marzoli GA, Oberto G, Brunetti MM. Diacerein effects on the cardiovascular function of the conscious dog following repeated oral administration [study report]. Rome (Italy): RTC Research Toxicology Centre. Rome (Italy); 2009., p. 81.